Growth Ratio Summary

Growth Score : 6.00

Sotac Pharmaceuticals demonstrates promising growth, driven by revenue and operating profit increases. However, the negative EPS and net income growth rates raise concerns about the sustainability of this growth. The company shows good asset growth. Addressing the underlying factors affecting profitability is vital for ensuring long-term growth and financial stability. The pharmaceuticals industry's competitive landscape and regulatory changes may influence growth prospects.

Financial Ratio Summary

Financial Score : 2.40

Sotac Pharmaceuticals' financial metrics indicate a need for improvement. The low adjusted EPS , cash EPS and book value per share, along with the lack of dividend payments, raise concerns about the company's financial performance and shareholder value. The high capital expenditures suggest significant investments, but their impact on profitability needs to be carefully monitored. Addressing these financial challenges is crucial for enhancing investor confidence and ensuring long-term sustainability.

Profitability Ratio Summary

Profitability Score : 9.80

Sotac Pharmaceuticals demonstrates strong profitability, indicating efficient operations and effective cost management. High gross profit margin, ROCE, ROE, and ROA, coupled with strong operating and net margins, suggest a solid financial performance. This profitability provides a foundation for future growth and expansion. Maintaining these profitability levels is crucial for ensuring long-term success in the competitive healthcare industry.

Efficiency Ratio Summary

Efficiency Score : 3.33

Sotac Pharmaceuticals' efficiency ratios present a mixed picture. While the inventory turnover is average, the fixed asset and capital turnover ratios are low, suggesting underutilization of assets. The high number of days sales in inventory and receivable days indicate potential challenges in managing working capital. Optimizing asset utilization and improving working capital management are essential for enhancing operational efficiency and profitability.

Coverage Ratio Summary

Coverage Score : 5.60

Sotac Pharmaceuticals' coverage ratios present a mixed scenario. While the interest coverage shows the company can meet its interest obligations, the lack of equity dividend coverage is a concern. Prioritizing both interest and dividend coverage is essential for maintaining financial stability and attracting investors. Industry-specific factors, such as regulatory changes, can influence coverage ratios.

Solvency Ratio Summary

Solvency Score : 10.00

Sotac Pharmaceuticals exhibits excellent solvency, indicating a strong position in managing its long-term debt obligations. The low debt ratio and debt-to-equity ratio, coupled with a high equity ratio, suggest a conservative approach to financing and a solid capital structure. This financial stability provides a buffer against economic downturns and allows the company to pursue growth opportunities with confidence.

Liquidity Ratio Summary

Liquidity Score : 3.86

The liquidity position of Sotac Pharmaceuticals needs attention. While the quick ratio shows some ability to meet short-term obligations with its most liquid assets, the current and cash ratios indicate potential difficulties in covering immediate liabilities. The negative operating cash flow ratio further exacerbates these concerns. The company might face challenges in managing its working capital effectively, affecting its day-to-day operations and financial flexibility.